Opinion

Video

Role of Biomarkers in Graft-vs-Host Disease

Author(s):

Hana Safah, MD,Corey S. Cutler, MD, MPH, FRCPC

Corey Cutler, MD, MPH, discusses the role of prognostic markers in graft-vs-host disease and how they can potentially inform treatment selection.

Related Videos
Minoo Battiwalla, MD, MS
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.
Nancy U. Lin, MD, discusses the safety data from DESTINY-Breast12 with T-DXd for HER2+ advanced/metastatic breast cancer with or without brain metastases.
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
2 KOLs are featured in this series.
Daniel DeAngelo, MD, PhD
Related Content
Natural Killer Cells in Ovarian Cancer | Image Credit: © Dr_Microbe - stock.adobe.com
November 18th 2024

First Clinical Trial of “Memory Like” Natural Killer Cells in Ovarian Cancer Opens at Dana-Farber

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Acute Myeloid Leukemia
November 15th 2024

Venetoclax Plus 10-Day Decitabine Produces Responses in High-Risk MDS, AML

Narjust Florez, MD
September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

Alex F. Herrera, MD
November 14th 2024

Data for Nivolumab Plus AVD Could Help Harmonize Treatment of Older and Younger Advanced-Stage Hodgkin Lymphoma

Jennifer Amengual, MD, Herbert Irving Assistant Professor of Medicine, Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center
November 13th 2024

Real-World Experience With CAR T Varies From Trials in DLBCL